SLC7A11 and prostate carcinoma: Immunohistochemical analysis indicated that SLC7A11 expression was lowest in benign prostate (BP) samples, moderately elevated in prostate cancer samples with Gleason scores <7, and significantly increased in tumors with Gleason scores of 7 and >7, with the highest levels observed in the >7 group (Fig. 1P).